Bactrim Roche

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bactrim Roche

Property Description
Active Ingredients Sulphamethoxazole, Trimethoprim
Form Tablets, Oral suspension
Pharmacological Class Fixed-dose combination antibiotic (Antimicrobial)
Common Use Treating bacterial infections
Origin Synthetic

What Type of Antibiotic is Bactrim Roche?

The medication commercially known as Bactrim Roche is an antibiotic preparation with the generic name Co-trimoxazole. It is defined as a synthetic antibacterial combination product and belongs to the broader antimicrobial class of drugs. This designation confirms its role as a strategically paired formulation with medical literature confirming its established efficacy against a broad spectrum of susceptible bacteria, a property clinically recognized for decades. This means the medication is structurally optimized to be a powerful tool in eliminating disease-causing bacteria.


Composition, Origin, and Synergistic Function

The two primary active ingredients are Sulphamethoxazole, derived from the sulfonamide class, and Trimethoprim, a benzylpyrimidine derivative. These compounds are wholly synthetic and formulated for oral use, available as standard tablets, DS (Double Strength) tablets, and an oral suspension. The fundamental strength of the medicine lies in its synergistic effect: the two components sequentially block essential steps in the bacteria's process of creating folate. This dual-action mechanism is supported by pharmacological studies demonstrating a superior, bactericidal (bacteria-killing) action compared to using either component individually. This potent antimicrobial force forms the general purpose of the medication: effectively clearing systemic bacterial infections.

Regulatory References

  1. Co-trimoxazole: MedlinePlus Drug Information

What side effects are possible with Bactrim Roche?

Possible side effects and safety information

The official safety profile for Co-trimoxazole (Bactrim Roche) is organized by government regulatory agencies based on frequency and affected body systems.

Adverse Reaction Scope

Component Description
Frequency Classification Common reactions documented in regulatory sources include headache, nausea, diarrhea, and skin rash. Uncommon reactions include vomiting. Severe reactions are generally classified as Rare or Very Rare (e.g., serious cutaneous reactions).
System-Organ Classes Involved Adverse reactions are officially categorized across several major systems, including Blood and lymphatic system disorders, Gastrointestinal disorders, Skin and subcutaneous tissue disorders, Nervous system disorders, and Hepatobiliary disorders.
Serious Adverse Reactions Officially documented serious reactions include severe cutaneous events, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), as well as severe blood dyscrasias like Agranulocytosis and Aplastic Anaemia.

Safety Considerations and Restrictions

Regulatory documents highlight specific safety considerations for certain patient groups. Older adults are documented as having an increased risk of severe adverse reactions, particularly concerning the blood and renal systems. Caution is explicitly required for patients with pre-existing renal impairment or folate deficiency.

The medication is contraindicated by regulatory authorities in documented severe hepatic damage and in severe renal insufficiency where function cannot be safely monitored. Severe adverse reactions are sometimes associated with long-term exposure or high doses.

This framework establishes the scope and severity of known, potential risks associated with the medicine’s use, strictly as defined in government-approved prescribing information.

Overdose and Emergency Response

The official regulatory documents state that an overdose of Co-trimoxazole (Bactrim Roche) may manifest in several ways, classified into acute and chronic presentations. Acute overdose commonly includes gastrointestinal symptoms such as nausea, vomiting, and loss of appetite (anorexia), alongside fever and mental signs like confusion or, in severe cases, loss of consciousness. Other documented signs include hematuria (blood in the urine) and jaundice (yellowing of the skin or eyes). Chronic toxicity, resulting from prolonged high-dose exposure, can lead to serious bone marrow depression and megaloblastic anemia.

Any suspected overdose requires the user to seek immediate medical attention. Regulatory guidance mandates calling the Poison Help Line, and immediate contact with emergency services is required if the individual experiences a seizure, collapse, trouble breathing, or cannot be awakened. Management is centered on symptomatic and supportive treatment, as no specific antidote is known for the combination. Documented procedures may involve gastric lavage and the administration of activated charcoal to limit absorption. The severe hematologic effects are managed with Leucovorin Calcium. Furthermore, elderly patients are identified as being at an increased risk of severe toxicity, often requiring regular monitoring of hematology and urinalysis.

Therapeutic Uses of Bactrim Roche

Quick Facts

  • May be prescribed to manage acute exacerbations of chronic bronchitis.
  • Utilized for the therapeutic management of certain urinary tract infections.
  • Has established use in treating traveler's diarrhea in adults.
  • Applied in the management and prevention of Pneumocystis jirovecii pneumonia.

Bactrim Roche is a therapeutic agent that supports the body's resolution of various bacterial infections. Its established uses include the management of certain bacterial infections in the urinary tract, helping to address discomfort and aid in clearance. This agent may also be prescribed for the therapeutic management of acute otitis media in pediatric patients when clinically appropriate.

In adults, it is also utilized for addressing acute infective exacerbations of chronic bronchitis. Furthermore, Bactrim Roche has established indications for the management of gastrointestinal infections, such as shigellosis, as well as for traveler's diarrhea in adult patients. A key application is its role in the treatment and prophylaxis of Pneumocystis jirovecii pneumonia, particularly in individuals who are immunosuppressed.

Eligibility and Restrictions for Use

Who Can and Cannot Use Bactrim Roche?

Regulatory agencies define specific patient populations for whom Co-trimoxazole (Bactrim Roche) use is either permitted, restricted, or strictly contraindicated. Eligibility is not solely determined by the infection being treated but by the patient's underlying physiological status and health history.


Official Non-Eligibility and Contraindications

Classification Population or Condition
Absolute Contraindication Infants less than two months of age (risk of kernicterus)
Absolute Contraindication Patients with known hypersensitivity to trimethoprim or sulfonamides
Absolute Contraindication Severe hepatic damage or marked liver parenchymal damage
Absolute Contraindication Severe renal insufficiency where creatinine clearance is <15 mL/min
Absolute Contraindication Documented megaloblastic anemia due to folate deficiency

Restricted Use and Special Populations

Use is not recommended or requires caution in several groups, including pregnant patients in the first trimester and near term (third trimester), and nursing mothers whose infant is under two months or has G6PD deficiency. Caution is required in older adults and patients with G6PD deficiency, porphyria, or conditions predisposing to hyperkalemia.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Co-trimoxazole (Sulfamethoxazole/Trimethoprim) has officially documented interaction patterns based on metabolic pathway interference and pharmacodynamic effects, as outlined in government regulatory labeling.

Contraindicated Combination: Co-administration with Dofetilide is formally prohibited due to the risk of significantly increasing Dofetilide plasma concentrations.

Pharmacokinetic Interactions: The Sulfamethoxazole component is documented to inhibit CYP2C9, which can potentiate the anticoagulant effect of Warfarin and reduce the clearance of Phenytoin. The Trimethoprim component is an inhibitor of CYP2C8, affecting oral hypoglycemics like Repaglinide, and inhibits the renal transporter OCT2, increasing the exposure of substrates such as Lamivudine, Metformin, and Amantadine.

Pharmacodynamic Interactions: Co-administration with ACE Inhibitors or Potassium-Sparing Diuretics significantly increases the risk of hyperkalaemia (high serum potassium) due to additive effects. Combining this medicine with other anti-folate agents, such as Methotrexate or high-dose Pyrimethamine, increases the risk of hematologic toxicity. The regulatory profile notes that the increase in Digoxin plasma levels is observed specifically in a proportion of elderly patients.

Mechanism of Action

The core mechanism of action relies on the synergistic dual-step blockade of the microbial pathway required to synthesize folic acid. The combination of Sulphamethoxazole and Trimethoprim sequentially inhibits two critical enzymes: Dihydropteroate Synthase (DHPS) and Dihydrofolate Reductase (DHFR). This process starves the microbial cells of the necessary cofactors, leading to the rapid cessation of DNA and protein synthesis.

This dual-blockade strategy creates a synergistic potentiation, meaning the combined effect is magnified beyond simple additivity. By halting the synthesis of nucleic acids, the mechanism moves beyond simply stopping growth (bacteriostatic) to actively killing the microbial population (bactericidal). This high-efficiency cascade results in the rapid cessation of growth and viability of microbial populations in physiological systems.

A separate, off-target mechanism involves the Trimethoprim component's direct physical interaction with the Epithelial Sodium Channel (ENaC) in the kidney tubules. This interaction effectively blocks the channel, reducing sodium reabsorption and consequently impairing the kidney's ability to excrete potassium. This distinct physiological consequence alters the body's electrolyte homeostasis, leading to a tendency toward potassium retention.

Dosage and Administration Information

The use of co-trimoxazole (Bactrim Roche) is governed by specific administration protocols. The medication is delivered via the oral route (as tablets or suspension) and by intravenous (IV) infusion for severe cases or when oral intake is compromised. The standard adult dose for most acute infections, such as certain urinary tract infections, is one Double Strength (DS) tablet (800 mg SMX / 160 mg TMP) administered every 12 hours.

In cases of severe infection, such as Pneumocystis jirovecii Pneumonia (PJP), the dosage requires calculation based on the patient's body weight, utilizing a high-dose regimen of 15 to 20 mg of the trimethoprim component per kg per day, which is then divided into doses given every 6 to 8 hours.

The duration of the course is mandated by the infection type, spanning 5 days for traveler's diarrhea to 10 to 14 days for acute bronchitis, and 14 to 21 days for PJP treatment. Procedural instructions mandate that the oral dose may be taken with or without food, but patients must maintain adequate fluid intake throughout the course. For intravenous administration, the concentrate must be diluted and infused slowly over a period of 60 to 90 minutes; rapid injection is prohibited. Furthermore, a 50% dose reduction is required for patients over 12 years old with moderate renal impairment (creatinine clearance 15 to 30 mL/min) to manage drug clearance.

Recent Clinical Evidence

Research evidence / Overview of Studies for Bactrim Roche


Evidence for Use in Urinary Tract and Acute Ear Infections

The research base for Urinary Tract Infections (UTIs) and Acute Otitis Media (AOM) relies on clinical trials and established regulatory data. Studies for UTIs measured clinical resolution and the elimination of susceptible organisms, and research examined how this combination compares against using trimethoprim alone. For AOM, studies focused solely on pediatric patients, evaluating the resolution of ear infection symptoms. A key area of uncertainty across these indications is the continuous challenge of emerging antimicrobial resistance.

Evidence for Preventing and Treating Pneumocystis Pneumonia (PJP/PCP)

The evidence for Pneumocystis pneumonia is substantial, based on Randomized Controlled Trials (RCTs) and long-term prophylaxis (prevention) studies. Research monitored critical outcomes such as overall survival and the rate of infection incidence, primarily in immunosuppressed individuals, including patients with HIV. Evidence concerning the efficacy of treatment (versus prevention) may be less extensive in some subgroups.

Evidence for Respiratory and Gastrointestinal Infections

Clinical trials have examined this medicine for Acute Exacerbations of Chronic Bronchitis, focusing on the resolution of acute symptoms. Studies for Shigellosis and Traveler's Diarrhea also measured symptom resolution and bacteriological clearance. Research for chronic bronchitis exacerbations remains limited to the acute event, providing no insight into long-term management. Continuous monitoring is needed due to resistance concerns in relevant bacteria.

Long-Term Studies and Evidence in Specific Patient Groups

The most extended follow-up data comes from PJP/PCP prophylaxis studies, which monitored patients for intermediate to long-term periods. Outside of these prevention settings, long-term effects are not fully established. Research has also specifically monitored older adults (geriatric subjects) for drug clearance and assessed unique clinical patterns in highly immunosuppressed groups.

What is Still Uncertain About Bactrim Roche Research

Evidence quality varies across studies, and regulatory bodies have noted a limited volume of specific clinical trials for certain indications. Research consistently identifies the challenge of antimicrobial resistance as a primary area of uncertainty requiring continuous investigation. Study results reflect group patterns and do not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Bactrim Roche (FAQ)


Q: Does Bactrim Roche treat viral infections?

A: According to the official product information, Bactrim Roche (sulfamethoxazole and trimethoprim) is an antibacterial combination product. It is intended to treat infections that are caused by susceptible bacteria. The drug is not indicated to treat viral infections, such as the common cold or the flu.


Q: What does it mean if my symptoms don't improve after a few days on Bactrim Roche?

A: Regulatory documents indicate that antibacterial drugs should only be used to treat infections caused by bacteria that are susceptible to the medication. If your symptoms do not begin to improve, official information suggests this may be due to the infection being caused by a drug-resistant bacterium or a pathogen that the drug is not designed to treat.


Q: Are there any specific foods or drinks to avoid while taking Bactrim Roche?

A: Official patient information notes that certain medicines may interact with alcohol (ethanol). In the case of Bactrim Roche, regulatory text advises that using alcohol or tobacco with this medicine may cause interactions to occur, or may require a change in how the medicine is used.


Q: Is it true that Bactrim Roche can affect blood sugar levels?

A: The drug's labeling confirms that it interacts with certain oral hypoglycemic medications used to manage blood sugar. Furthermore, official safety information lists symptoms such as shakiness and unusual tiredness among the potential adverse events, which are sometimes associated with changes in blood sugar.


Q: Is Bactrim Roche safe to use during pregnancy, according to official sources?

A: Official warnings state that this drug may cause fetal harm if used during pregnancy, and its use may be contraindicated in certain trimesters. The warnings note that exposure, especially in the first trimester and near term, is associated with potential risks, including birth defects and kernicterus.


Q: What is the connection between Bactrim Roche and G6PD deficiency?

A: The drug's official labeling advises caution when used in patients who have Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency. The labeling indicates the medication has the potential to cause hemolytic anemia (a serious blood disorder) in individuals with this pre-existing condition.


Q: Why does the packaging for Bactrim Roche include a warning about serious skin reactions?

A: The packaging includes warnings due to the risk of rare but serious, sometimes fatal, hypersensitivity events. These officially documented serious cutaneous adverse reactions (SCARs) include conditions like Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).


Q: Does Bactrim Roche carry a Black Box Warning, and if so, what is it for?

A: Yes, the official prescribing information includes a Boxed Warning, the most serious type of warning mandated by the FDA. This warning highlights the risk of fatal adverse reactions, including severe skin reactions and serious blood disorders known as blood dyscrasias.


Q: What is the difference between an allergic reaction and a common side effect of Bactrim Roche?

A: Official documents classify adverse events by type and severity. Common side effects, like nausea or diarrhea, are typically listed as expected adverse reactions. In contrast, an allergic reaction is officially classified as a hypersensitivity event, which represents an immune response and is associated with the most serious warnings.


Q: How is Bactrim Roche categorized in terms of pregnancy risk, according to the FDA?

A: The FDA classified Bactrim Roche as Pregnancy Category D. This indicates that there is positive evidence of human fetal risk based on human data. However, the potential benefits of the drug may sometimes be considered to outweigh the risks.


Q: What is the difference between Bactrim Roche and Septra?

A: Bactrim Roche and Septra are different brand names but contain the exact same active ingredients: the fixed-dose combination of sulfamethoxazole and trimethoprim (known generically as co-trimoxazole).


Q: Is it common to feel tired while taking Bactrim Roche?

A: Yes, official safety profiles list fatigue or unusual tiredness as a potential side effect associated with the medication's use.


Q: Can Bactrim Roche cause sensitivity to the sun?

A: Yes, the prescribing information lists photosensitivity as a reported adverse effect. This means the skin may be unusually sensitive to sun exposure or ultraviolet (UV) light while taking the medication.


Q: Can Bactrim Roche affect my mood or sleep?

A: Official safety information includes potential central nervous system side effects. These reactions, which may affect mood or sleep, include drowsiness, confusion, mental depression, anxiety, and trouble sleeping (insomnia).


Q: What happens if I take Bactrim Roche with a multivitamin?

A: Bactrim Roche interferes with the body’s ability to use folic acid (Vitamin B9) in certain cells. Official guidance indicates that due to the drug's mechanism, the addition of a folate supplement may be warranted in specific patient situations.


Q: If I miss a dose of Bactrim Roche, what do official instructions say to do?

A: The official instructions for a missed dose state that you should use the medicine as soon as you realize you missed it. However, if it is almost time for your next scheduled dose, you should skip the missed dose and return to your regular dosing schedule. Do not take two doses at the same time.


Q: Can Bactrim Roche affect the results of certain lab tests?

A: Yes, adverse reactions noted in the drug's safety profile include effects on blood electrolyte levels. This can result in changes to lab values such as high potassium (hyperkalemia) and low sodium (hyponatremia), as well as increased kidney function markers like uremia.


Q: What are the general safety facts regarding Bactrim Roche and contraceptive pills?

A: Regulatory documents describe a known interaction between the medication and certain hormone treatments. Bactrim Roche may reduce the effectiveness of estrogen-containing medications, which include some types of oral contraceptive pills.


Q: Is Bactrim Roche safe for people with known heart conditions?

A: While heart conditions are not listed as an absolute contraindication, the prescribing information carries a specific warning about the risk of hyperkalemia (high potassium). The risk of hyperkalemia is a factor considered during its use.


Q: Does official prescribing information mention any impact on fertility from Bactrim Roche?

A: Yes, the official prescribing information includes a dedicated section within the Nonclinical Toxicology area that specifically addresses studies on the 'Impairment of Fertility.'


Q: What are the components of Bactrim Roche, besides the active ingredients?

A: The official description section of the drug's labeling lists the active ingredients (sulfamethoxazole and trimethoprim) and the inactive ingredients (excipients). For example, the inactive ingredients in the tablet form typically include docusate sodium, sodium benzoate, magnesium stearate, and pregelatinized starch.


Q: What are the risks of taking Bactrim Roche when severely dehydrated?

A: The drug's labeling warns of the risk of serious electrolyte abnormalities, including hyperkalemia (high potassium) and hyponatremia (low sodium). Due to the risk of these electrolyte problems, adequate hydration is mandated, as dehydration can worsen these potential imbalances.

How should Bactrim Roche be stored and disposed of?

Storage and Disposal of BACTRIM (Sulfamethoxazole and Trimethoprim)

Official Storage Requirements

BACTRIM tablets and oral suspension must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medication must be kept in its container, which should be tightly closed and stored out of the sight and reach of children.

Formulation Prohibited Environments
Oral Suspension Do not refrigerate; do not freeze; protect from light.
Tablets Must be dispensed in a tight, light-resistant container.

Disposal

Official guidelines mandate the safe disposal of unused or expired BACTRIM. Users are instructed to ask a healthcare professional or follow established governmental guidelines for discarding the medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bactrim Roche found in:

A-Z Index: